Skip to main content
Premium Trial:

Request an Annual Quote

Almaden Genomics: Ellen Gordon

Almaden Genomics has named Ellen Gordon VP and head of business development. As such, she will lead the fledgling bioinformatics firm's efforts to partner with genomic R&D companies and laboratories on target and biomarker discovery. A veteran of the pharmaceutical and biotech industries, Gordon previously was VP of global accounts at BrightInsight, maker of a software platform for digital health apps in regulated environments. She also briefly served as digital ventures lead at Memorial Sloan Kettering Cancer Center.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.